What We Can Learn From Bill Ackman Walking Away From Valeant Pharmaceuticals Intl Inc.

Investors can learn a lot from Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

| More on:
The Motley Fool

Recently, it was announced that hedge fund manager Bill Ackman sold his firm’s entire stake in Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). By selling his final position, he has done what many investors hate to do: he locked in losses.

Almost every investor has at least one position in their portfolio that is held at a loss. When an investor enters a position and sees the investment decline in value by say 20%, it is important to understand what needs to happen for the investor to be able to recoup their original investment. Using very simple math, an investment of $100 which declines by 20% to $80 needs to return to $100 for the investor to be even.

Assuming we hit the reset button here, a new investor may purchase the shares at $80 and get a $20 return divided by the initial outlay of $80, which translates to a return of 25%, not 20%!

For investors holding positions that are slightly at a loss, the amount a stock must come back to make up the loss is nothing more than a rounding error. Once it gets beyond 20-25%, however, the numbers are a little more serious.

With a loss of 10% as an example, the return must be 10/90 = 11.1%, meaning a difference of 1.1% — a very minor number.

Valeant shares have declined close to 90% since Ackman made the initial investment, translating to a return of (90/10) = 900% for his firm to get back to even. Although we’ve seen the hedge fund manager do fantastic things in the past, any investor hoping for a return of 900% is dreaming.

The amount of interest expenses as a percentage of revenue is simply too high for this company to survive over the long term, translating to a desperate need to either drastically increase revenue or repay debt.

As it is difficult to increase revenues, the second option is to pay off debt. Debt is close to $30 billion, and that can only mean selling assets or doing a secondary share issue. The challenge with this possibility is that Valeant has $30 billion in debt but a market capitalization of only approximately $5 billion. If the float were to double, the debt would only be reduced by approximately 16.5% or so.

And it seems the company is in for the fight of a lifetime after losing one of the heavyweight members of the board of directors.

Although the company has many excellent products to offer consumers, the reality is, the debt burden is simply too much to carry at this point. Bankruptcy may take months from here, but it’s inevitable — the fat lady will sing!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Goldsman has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Target. Stand out from the crowd
Investing

The Best Stocks to Invest $2,000 in Right Now

Despite the uncertain outlook, these three stocks would be excellent additions to your portfolios.

Read more »

financial freedom sign
Dividend Stocks

RRSP Secrets: 3 Millionaire Strategies Revealed

The RRSP helps Canadians save for retirement and proper utilization can make you a millionaire over time or when you…

Read more »

dividends grow over time
Dividend Stocks

3 Fabulous Dividend Stocks to Buy in April

If you're looking to boost your passive income while interest rates are elevated, here are three of the best dividend…

Read more »

calculate and analyze stock
Dividend Stocks

2 Top TSX Dividend Stocks That Still Look Oversold

These top TSX dividend-growth stocks now offer very high yields.

Read more »

Dollar symbol and Canadian flag on keyboard
Dividend Stocks

Beginner Investors: 5 Top Canadian Stocks for 2024

New to the stock market? Here are five Canadian companies to build a portfolio around.

Read more »

Increasing yield
Dividend Stocks

Want to Gain $1,000 in Annual Dividend Income? Invest $16,675 in These 3 High-Yield Dividend Stocks

Are you looking for cash right now? These are likely your best options to make over $1,000 in annual dividend…

Read more »

TELECOM TOWERS
Dividend Stocks

Passive-Income Investors: The Best Telecom Bargain to Buy in May

BCE (TSX:BCE) stock may be entering deep-value mode, as the multi-year selloff continues through 2024.

Read more »

edit Safe pig, protect money
Dividend Stocks

3 Safe Dividend Stocks to Own for the Next 10 Years

These Canadian dividend gems could help you earn worry-free passive income over the next decade.

Read more »